Study on the microRNA Expression Level in Postmenopausal Osteoporosis

Completed

• Conditions: Postmenopausal Osteoporosis
• Interventions: Other: osteoporosis

• Registration Number: NCT02128009
• Lead Sponsor: Fujian Academy of Traditional Chinese Medicine

Brief Summary

The miRNA plays an important regulation role in gene expression, and also closely related to bone metabolism. Previous research found that postmenopausal osteoporosis with kidney Yin deficiency syndrome (POP) is associated with CLCF1 gene. This project proposed by bioinformatics prediction CLCF1 targeted regulation of miRNAs, and use the 3 'UTR dual luciferase report system for target validation, aimed at the miRNA levels to explore postmenopausal osteoporosis molecular mechanism with kidney Yin deficiency syndrome.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-02
• Study First Submitted: 2014-03-14
• Study First Submitted QC: 2014-04-30
• Study First Posted: 2014-05-01
• Primary Completion: 2016-12
• Study Completion: 2017-01
• Status Verified: 2019-02
• Last Update Submitted: 2019-02-25
• Last Update Posted: 2019-02-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

• The Participants who volunteer to be test subjects, and can accept experimental drugs, and promise to finish the course should sign the informed consent.
• Female ages 45 to 75 had gone through natural menopause before two years
• In accordance with the western medicine diagnostic criteria of osteoporosis and belong to kidney Yin deficiency syndrome differentiation of traditional Chinese medicine certificate;
• In accordance with the western medicine diagnostic criteria;
• In accordance with TCM diagnostic methods; .If any of the above answers are no, The subjects couldn't in the study.

Exclusion Criteria

• Do not accord with standard of the western medicine diagnosis and TCM diagnostic methods
• Age: <44 and > 76 years old;
• With hyperparathyroidism, osteomalacia, rheumatoid arthritis, multiple myeloma and other serious complications such as secondary osteoporosis; Late or deformity, disability, loss of labor;
• With cardiovascular, cerebrovascular, liver, kidney and hematopoietic system and other serious primary diseases;
• Psychosis or alzheimer's patients;
• Nearly three months, the use of hormone replacement therapy (HRT) and taking calcitonin, nearly six months has used double phosphonic acid salt for 15 days, etc.;
• This medicine allergic constitution or composition of known to have allergies;
• In a critical condition, It's difficult to make exact evaluators to efficacy and safety of the new drugs;

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
osteoporosis,non-osteoporosis	osteoporosis	-

Primary Outcome Measures

Name	Time	Method
microRNA expression lever in the Peripheral Blood	one year

Trial Locations

Locations (1)

Fujian Institute of Trational Chiness Medicine; 🇨🇳 Fuzhou, Fujian, China